Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.05 – $0.27
29% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50.5K | $34.2K | $1.5M | $2.0M | $1.2M | $4.5M | $3.8M | $0 |
| Cost of revenue | $1.6K | $801 | $672 | $3.2K | $73.4K | $442.0K | $210.6K | $92.3K |
| Gross profit | $48.9K | $33.4K | $1.5M | $2.0M | $1.1M | $4.0M | $3.6M | −$92.3K |
| Gross margin | 96.8% | 97.7% | 100.0% | 99.8% | 93.8% | 90.1% | 94.4% | — |
| R&D | $678.4K | $1.1M | $2.2M | $3.8M | $4.7M | $5.8M | $7.5M | $9.1M |
| Operating income | −$1.9M | −$2.3M | −$2.3M | −$3.6M | −$6.2M | −$4.4M | −$6.5M | −$13.2M |
| EBITDA | −$1.9M | −$2.3M | −$2.3M | −$3.6M | −$7.3M | −$4.6M | −$6.8M | −$13.1M |
| Net income | −$1.9M | −$2.2M | −$2.3M | −$3.6M | −$6.2M | −$4.5M | −$6.6M | −$7.7M |
| Net margin | -3704.8% | -6484.6% | -148.8% | -183.7% | -524.8% | -101.1% | -173.7% | — |
| EPS (diluted) | -0.04 | -0.04 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $0 | $-0.02 | $-0.02–$-0.02 | 1 |
| 2028 | $10M | $-0.01 | $-0.01–$-0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
AMPLIA THERAPEUTICS LTD
No one on the platform currently holds INNMF.
No tracked institution reports a position in INNMF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2018-05-03 | 1-for-10reverse |
No one on the platform has traded INNMF yet.
| +0.00% |
| $2M |
| — |
| HBPCFHelix BioPharma Corp. | $1.71 | +0.00% | $131M | — |
| OTLCOncotelic Therapeutics, Inc. | $0.04 | +1.53% | $20M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 4.1× sales vs its 7.0× historical median P/S.
Fair value ≈ $0.20 · price $0.12 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.